N. Vogelzang

1.7k total citations
47 papers, 1.2k citations indexed

About

N. Vogelzang is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, N. Vogelzang has authored 47 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 16 papers in Surgery and 16 papers in Oncology. Recurrent topics in N. Vogelzang's work include Prostate Cancer Treatment and Research (14 papers), Testicular diseases and treatments (11 papers) and Neuroblastoma Research and Treatments (6 papers). N. Vogelzang is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Testicular diseases and treatments (11 papers) and Neuroblastoma Research and Treatments (6 papers). N. Vogelzang collaborates with scholars based in United States, United Kingdom and France. N. Vogelzang's co-authors include Susan Halabi, George J. Bosl, Nancy L. Geller, Emily Crawford, Dean F. Bajorin, Lawrence H. Einhorn, Paul J. Catalano, Patrick J. Loehrer, Craig R. Nichols and Eric J. Small and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Radiology.

In The Last Decade

N. Vogelzang

47 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. Vogelzang United States	15	707	519	391	270	258	47	1.2k
Tania Mariani United States	7	443 0.6×	580 1.1×	486 1.2×	203 0.8×	154 0.6×	8	999
J Pény France	8	449 0.6×	638 1.2×	405 1.0×	448 1.7×	96 0.4×	14	1.2k
M. Morse United States	11	539 0.8×	358 0.7×	164 0.4×	508 1.9×	172 0.7×	22	1.0k
M. Kuczyk Germany	12	798 1.1×	793 1.5×	659 1.7×	241 0.9×	50 0.2×	31	1.6k
Lionnel Geoffrois France	21	675 1.0×	844 1.6×	504 1.3×	595 2.2×	75 0.3×	90	1.6k
Jeff White United Kingdom	16	209 0.3×	279 0.5×	332 0.8×	363 1.3×	68 0.3×	53	898
Emmanuelle Fourme France	14	205 0.3×	216 0.4×	287 0.7×	311 1.2×	299 1.2×	30	1.2k
Albiruni Ryan Abdul Razak Canada	18	257 0.4×	375 0.7×	410 1.0×	661 2.4×	44 0.2×	100	1.3k
David Ransom Australia	18	173 0.2×	185 0.4×	583 1.5×	524 1.9×	155 0.6×	36	1.3k
Cristian Lolli Italy	19	263 0.4×	761 1.5×	274 0.7×	578 2.1×	104 0.4×	88	1.4k

Countries citing papers authored by N. Vogelzang

Since Specialization

Citations

This map shows the geographic impact of N. Vogelzang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Vogelzang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Vogelzang more than expected).

Fields of papers citing papers by N. Vogelzang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. Vogelzang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Vogelzang. The network helps show where N. Vogelzang may publish in the future.

Co-authorship network of co-authors of N. Vogelzang

This figure shows the co-authorship network connecting the top 25 collaborators of N. Vogelzang. A scholar is included among the top collaborators of N. Vogelzang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. Vogelzang. N. Vogelzang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hutson, Thomas E., et al.. (2014). Outcomes of Advanced Renal Cell Carcinoma Patients (Arcc) Treated with Mammalian Target of Rapamycin Inhibitor (Mtori) Therapy Following First-Line Pazopanib (Paz) in a Us Community Oncology Setting. Annals of Oncology. 25. iv295–iv295. 1 indexed citations

Dorff, Tanya B., Susan Groshen, Denice Tsao‐Wei, et al.. (2014). A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer and Prostatic Diseases. 17(4). 359–365. 9 indexed citations

O’Sullivan, Joe M., Dag Clement Johannessen, Anders Widmark, et al.. (2013). Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases : baseline prognostic factor subgroup analysis. European Journal of Cancer. 49. 3 indexed citations

Scosyrev, Emil, Benjamin Ely, V. O. Speights, et al.. (2012). Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology Re: Do Mixed Histological Features Affect Survival Benefit from Neoadjuvant Platinum-Based Combination Chemotherapy in Patients with Locally Advanced Bladder Cancer? A Secondary Analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). 14 indexed citations

Rathkopf, Dana E., K. N., Ulka N. Vaishampayan, et al.. (2009). Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 27(15_suppl). 5064–5064. 6 indexed citations

Sharma, Shringi, N. Vogelzang, James S. Beck, et al.. (2007). 702 POSTER Phase I pharmacokinetic and pharmacodynamic study of once-weekly IV LBH589. European Journal of Cancer Supplements. 5(4). 107–108. 5 indexed citations

Fink, Louis M., et al.. (2007). Coagulation markers D-dimer and prothrombin fragment 1.2 compared to disease and treatment status in prostate cancer patients. Journal of Clinical Oncology. 25(18_suppl). 15587–15587. 1 indexed citations

Picus, Joel, Susan Halabi, Eric J. Small, et al.. (2006). Long term efficacy of peripheral androgen blockade on prostate cancer: CALGB 9782. Journal of Clinical Oncology. 24(18_suppl). 4573–4573. 1 indexed citations

Mulder, P H de, Jan Roigas, Silke Gillessen, et al.. (2006). A phase II study of sunitinib administered in a continuous daily regimen in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 24(18_suppl). 4529–4529. 31 indexed citations

10.

Lara, Primo N., Jeff Longmate, Walter M. Stadler, et al.. (2004). Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291. Journal of Clinical Oncology. 22(14_suppl). 4647–4647. 1 indexed citations

11.

Humphrey, Peter A., Susan Halabi, Joel Picus, et al.. (2004). Scatter factor/hepatocyte growth factor as a prognostic indicator in metastatic prostate cancer: A plasma study in CALGB 9480. Journal of Clinical Oncology. 22(14_suppl). 9613–9613. 1 indexed citations

12.

Park, Dongsu, Charles J. Ryan, M. Eileen Dolan, N. Vogelzang, & Walter M. Stadler. (2002). A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemotherapy and Pharmacology. 50(2). 160–162. 15 indexed citations

13.

Kornblith, Alice B., James E. Herndon, E Zuckerman, et al.. (2001). The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study. Annals of Oncology. 12(5). 633–641. 46 indexed citations

14.

George, Daniel J., Susan Halabi, Timothy F. Shepard, et al.. (2001). Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.. PubMed. 7(7). 1932–6. 214 indexed citations

15.

Nichols, Craig R., Paul J. Catalano, Emily Crawford, et al.. (1998). Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.. Journal of Clinical Oncology. 16(4). 1287–1293. 204 indexed citations

16.

Stadler, Walter M., Derek Raghavan, Ellis Levine, et al.. (1995). 1152 Gemcitabine in the treatment of patients with advanced transitional cell carcinoma: A phase II study. European Journal of Cancer. 31. S241–S241. 7 indexed citations

17.

Fleming, Gini F., Mark J. Ratain, Sean M. O’Brien, et al.. (1994). Phase I Study of Adozelesin Administered by 24-Hour Continuous Intravenous Infusion. JNCI Journal of the National Cancer Institute. 86(5). 368–372. 33 indexed citations

18.

Sesterhenn, Isabell A., R B Weiss, F. K. Mostofi, et al.. (1992). Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study.. Journal of Clinical Oncology. 10(1). 69–78. 97 indexed citations

19.

Vogelzang, N., et al.. (1990). A third option in the management of patients with clinical stage I nonseminomatous germ cell tumor?. Journal of Clinical Oncology. 8(1). 4–8. 10 indexed citations

20.

Bosl, George J., Nancy L. Geller, N. Vogelzang, et al.. (1987). Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.. Journal of Clinical Oncology. 5(3). 436–440. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact